Roche Subsidiary Genentech Acquires Next-Generation CDK Inhibitor Portfolio from Regor Pharmaceuticals for $850 Million Upfront

Oct 01, 2024 07:32 CST Updated 07:32

Regor Therapeutics

Pharmaceutical R&D Developer

▎WuXiEdited by Kant Content Team

Today, Regor Therapeutics announced that it has reached an agreement with Genentech, a subsidiary of Roche.Genentech to Acquire Regor Therapeutics' Next-Generation CDK Inhibitor Pipeline for Breast Cancer Treatment。

According to the agreement, Regor Therapeutics will receive an upfront payment of up to 850 million US dollars and is eligible for development, regulatory, and commercial milestone payments. Genentech will be responsible for the clinical development, manufacturing, and global commercialization of the research projects. Regor will be responsible for continuing the two ongoing Phase 1 clinical trials until their completion.

Regor Therapeutics develops innovative and differentiated therapies for cancers, metabolic diseases, and autoimmune disorders with significant unmet medical needs, based on its proprietary Computer Accelerated Rational Discovery (CARD) platform. The company’s pipeline includes multiple therapies under research and development. Among them,RGT-419B is a CDK4 inhibitor with activity against CDK2 and is currently in Phase 1 clinical trials for the treatment of breast cancer. RGT-587 is a blood-brain barrier penetrant, selective CDK4 inhibitor for the treatment of brain metastases.

▲Regor Therapeutics' R&D Pipeline (Source: Regor Therapeutics Official Website)

The abstract presented at this year's annual meeting of the American Association for Cancer Research (AACR) shows that, in patients with recurrent refractory HR+/HER2- advanced breast cancer,RGT-419B monotherapy achieved a 28.6% partial response rate and a 44% clinical benefit rate, with no dose-limiting toxicity observed.

▲ To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer. Retrieved September 30, 2024, from https://www.regor.com/news/news.html#1

[2] Roche buys Regor’s CDK inhibitors for $850M upfront amid push to develop 20 ‘transformative’ medicines. Retrieved September 30, 2024, from https://endpts.com/roche-buys-regors-cdk-inhibitors-for-850m-upfront-amid-push-to-develop-20-transformative-medicines/

[3] Abstract PO3-18-06: First-in-human phase 1A study of RGT-419B, a next generation CDK4 inhibitor, in patients (pts) with hormone receptor positive (HR+) HER2- advanced/metastatic breast cancer (ABC) who progressed on prior CDK4/6 inhibitors (CDK4/6i). Retrieved September 30, 2024, from https://aacrjournals.org/cancerres/article/84/9_Supplement/PO3-18-06/744989/Abstract-PO3-18-06-First-in-human-phase-1A-study

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does WuXi AppTec support or oppose the views mentioned in the article. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or organizations in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain the reprint guidelines.

Share，PointLike，In View, Focusing on Global Biomedical Health Innovation